Agent Capital

Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101 Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphoma VIPER-101 was developed with Vittoria’s proprietary Senza5 platform that features CD5 modulation and a proprietary 5-day manufacturing process

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies IdeS IgG protease shows promise for Myasthenia Gravis, Immune Thrombocytopenia, and dozens of other IgG-driven autoimmune diseases. The wild type enzyme elicits potent anti-drug antibodies (ADA) that significantly impact redosing, whereas in a preclinical redosing model Cyrus’ candidate exhibits potent activity on repeat doses while eliciting no ADAs

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing Dose-dependent exposure was observed with evidence of robust brain penetration Data supports potential advancement into Phase 2 for neurodegenerative diseases characterized by neuroinflammation such as Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, and Alzheimer’s Disease

Congratulations to Vittoria Biotherapeutics, Inc. for closing their $25M round. We are thrilled to be working with such a great company! Nicholas Siciliano, Rosemary Mazanet, Christopher D. Hillyer, MD, Jay Mohr, Meg Wood, Valley Forge Investment Corp, Global BioAccess Fund, Hatch Biofund Management, Agent Capital, Tellus BioVentures, University of Pennsylvania

Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology Collaboration will leverage Flare Therapeutics’ proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules aimed at transcription factor targets in oncology   Flare Therapeutics to receive US $70 million upfront, and potential milestone payments exceeding US$1.8 billion, as well as royalties

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies “This milestone marks the first time that a durable in vivo CAR therapy has been used in the clinic. INT2104 has the potential to overcome ex vivo CAR therapy challenges with a single-dose, off-the-shelf, widely accessible therapy for the treatment of B cell malignancies enabled by Interius’s programmable platform." - Interius President and CEO, Phil Johnson, M.D. https://lnkd.in/ezvYT_Av

Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium SKY-1214, an IND-ready first-in-class FANCL/FANCI RNA splicing modulator, demonstrates tumor growth inhibition and regression to undetectable levels in NHL and difficult-to-treat MM xenograft mouse models

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 The poster presentation will highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers. The results support Phase 2 dose selection and continued clinical advancement of ADX-097. https://lnkd.in/e3NgR8RY

Cyrus Biotechnology Congratulates Co-Founder David Baker on winning the 2024 Nobel Prize in Chemistry along with Demis Hassabis and John Jumper from Google DeepMind for their extraordinary discoveries in designing and predicting protein structures. "By applying the technology created by Baker's team, Cyrus scientists are solving some of the biggest challenges of protein drugs, while also developing our own algorithms and new datasets in-house and with the Openfold AI consortium that Cyrus co-founded in 2022.” https://lnkd.in/eDA3HKRU

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Zenas. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $225.0 million. Zenas’ common stock is expected to begin trading on the Nasdaq Global Select Market on September 13, 2024 under the ticker symbol “ZBIO”. The offering is expected to close on September 16, 2024, subject to the satisfaction of customary closing conditions. In addition, Zenas has granted the underwriters a 30-day option to purchase up to an additional 1,985,294 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Morgan Stanley, Jefferies, Citigroup, and Guggenheim Securities are acting as joint book-running managers for the offering. SOURCE: Zenas Bio https://lnkd.in/e9YmZnwJ